# PSTPIP1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - *PSTPIP1* (CD2BP1) encodes a cytosolic adapter protein crucial for innate immunity, actin dynamics, and inflammatory signaling, with germline mutations causing autoinflammatory syndromes like PAPA and PAMI. - The protein's F-BAR domain interacts with pyrin to regulate the inflammasome, and its SH3 domain binds to PTPN22 and WASP, mediating cytoskeletal remodeling and immune cell function. - Pathogenic mutations, particularly in the F-BAR domain, lead to hyperphosphorylation and constitutive activation of the pyrin inflammasome, driving excessive IL-1β and S100A8/S100A9 (calprotectin) secretion. - Clinical manifestations are diverse, ranging from PAPA (arthritis, pyoderma gangrenosum, acne) to PAMI (hematological abnormalities, high calprotectin), with genotype-phenotype correlations guiding diagnosis and treatment. - Therapeutic strategies primarily target IL-1β with biologics like anakinra or canakinumab, though responses can be modulated by specific PSTPIP1 mutations and promoter microsatellite variations. - Emerging evidence implicates PSTPIP1 in host responses to viral infections, such as SARS-CoV-2, suggesting a broader role in inflammatory pathogenesis beyond autoinflammation. --- ## Executive Summary & Key Metadata The **PSTPIP1** gene (Proline-Serine-Threonine Phosphatase-Interacting Protein 1), also known as **CD2BP1** (CD2 Antigen Binding Protein 1), encodes a cytosolic adapter protein that is fundamentally important in the regulation of innate immune responses, actin cytoskeletal dynamics, and inflammatory signaling cascades. Germline mutations in PSTPIP1 are the molecular basis of a spectrum of rare, debilitating autoinflammatory disorders, most notably PAPA syndrome (Pyogenic sterile Arthritis, Pyoderma gangrenosum, and Acne), PAMI syndrome (PSTPIP1-Associated Myeloid-Related proteinemia Inflammatory syndrome), and related overlapping phenotypes such as PASH and PAPASH syndromes [1, 2, 3, 4, 5]. Beyond its canonical role in autoinflammation, emerging evidence implicates PSTPIP1 in cancer biology, particularly in renal cell carcinoma and lung adenocarcinoma, where its expression correlates with immune infiltration and patient prognosis [6, 7]. The protein operates as a molecular scaffold, linking the actin cytoskeleton to regulatory phosphatases and inflammasome components, thereby exerting pleiotropic effects on leukocyte adhesion, migration, podosome formation, and the secretion of potent pro-inflammatory alarmins such as S100A8/S100A9 (calprotectin) [8, 9, 10]. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | PSTPIP1 | | **UniProt Accession** | O43586 | | **Representative PDB ID** | True (Multiple structures available; see Section 2) | | **Chromosomal Locus** | 15q24.3 | | **Primary Molecular Function** | Cytoskeletal adapter protein; regulates actin dynamics, interacts with PTPN22/PEP, pyrin, and modulates IL-1β-mediated inflammatory responses. | | **Disease & Pathology Associations** | PAPA syndrome, PAMI syndrome, PASH syndrome, PAPASH syndrome, hidradenitis suppurativa, pyoderma gangrenosum, inflammatory bowel disease, and susceptibility to certain malignancies. | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *PSTPIP1* gene is located on the long arm of chromosome 15 at cytogenetic band **15q24.3**. The genomic reference sequence (GRCh38/hg38) places the gene between approximately 77,100,000 and 77,150,000 base pairs. The gene is oriented on the minus strand and spans roughly 50 kilobases of genomic DNA. The structure is complex, comprising at least **15 exons** that are variably spliced to produce multiple transcript variants. The canonical transcript (NM_003978.4) encodes a protein of 492 amino acids with a predicted molecular mass of approximately 54 kDa, although post-translational modifications, particularly phosphorylation, result in an observed molecular weight of approximately 65-70 kDa on SDS-PAGE [10, 11]. The promoter region of *PSTPIP1* is characterized by a lack of a canonical TATA box but contains multiple GC-rich regions and binding sites for ubiquitous transcription factors such as Sp1. Notably, the promoter contains a polymorphic **CCTG microsatellite repeat** in its 5' untranslated region. This repeat is of significant clinical interest; longer alleles of this CCTG repeat have been associated with susceptibility to asecesses and Crohn's disease in French cohorts, suggesting a transcriptional regulatory role that modulates gene expression levels in response to inflammatory stimuli [12, 13, 14]. ### 1.2 Alternative Splicing and Isoforms Alternative splicing of the *PSTPIP1* pre-mRNA generates several isoforms that differ in their C-terminal regions and, consequently, their protein-protein interaction capabilities. The major isoforms identified include: - **Isoform 1 (Canonical, 492 aa):** The full-length protein containing all functional domains, including the F-BAR domain, coiled-coil regions, and the SH3 domain. - **Isoform 2:** Lacks a portion of the C-terminal SH3 domain due to the use of an alternative splice acceptor site in exon 15. This isoform has altered binding affinity for CD2 and other SH3-binding partners. - **Isoform 3:** A shorter variant that skips exon 12, resulting in an in-frame deletion within the linker region between the coiled-coil and SH3 domains. This isoform may exhibit altered subcellular localization. Aberrant splicing of *PSTPIP1* has been directly implicated in disease pathogenesis. Nesterovitch et al. (2011) identified novel splice variants in patients with pyoderma gangrenosum that lacked exons encoding critical portions of the F-BAR domain. These splice variants produced truncated proteins that mislocalized within the cell and exerted a dominant-negative effect on wild-type PSTPIP1 function, leading to dysregulated actin dynamics and enhanced inflammatory cytokine production [15]. This highlights that not only missense mutations but also splicing defects contribute to the clinical heterogeneity of PSTPIP1-associated diseases. ### 1.3 Regulatory Elements and Epigenetic Control Beyond the promoter microsatellite, the *PSTPIP1* locus is regulated by several distal enhancer elements identified through chromatin state annotations (e.g., H3K27ac and H3K4me1 marks) in hematopoietic cell types. These enhancers are bound by transcription factors critical for myeloid and lymphoid development, including PU.1 and C/EBPα. The expression of PSTPIP1 is highly enriched in cells of the innate immune system, particularly neutrophils, monocytes, and macrophages, but is also present in T cells and endothelial cells [10, 16]. Epigenetic silencing via DNA methylation of the promoter region has been observed in certain cancer cell lines, correlating with reduced PSTPIP1 expression and potentially contributing to tumor immune evasion [6]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The PSTPIP1 protein is a member of the **Pombe Cdc15 homology (PCH) family** of adaptor proteins, characterized by an N-terminal F-BAR (Fes/CIP4 homology-Bin/Amphiphysin/Rvs) domain. The domain architecture from N-terminus to C-terminus is as follows: 1. **F-BAR Domain (Residues ~1-300):** This large, banana-shaped domain is the primary structural and functional unit of PSTPIP1. It mediates homodimerization and binds to cellular membranes, particularly those of the plasma membrane and endosomes, through electrostatic interactions with negatively charged phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2). The F-BAR domain is also the principal site for binding to the pyrin protein, a key component of the inflammasome. Pathogenic mutations in PAPA syndrome (e.g., A230T, E250K) cluster within this domain, specifically at the dimer interface or the membrane-binding concave surface, leading to hyperphosphorylation and altered binding kinetics [8, 11, 17]. 2. **Coiled-Coil Region (Residues ~300-370):** This region facilitates higher-order oligomerization and provides a flexible linker between the F-BAR domain and the C-terminal SH3 domain. It also contains binding sites for the tyrosine kinase c-Abl, which phosphorylates PSTPIP1 at Y344, a modification critical for its interaction with PTPN22 [10]. 3. **SH3 Domain (Residues ~380-492):** The Src Homology 3 domain is a small, globular module that mediates protein-protein interactions by binding to proline-rich motifs (PxxP) in target proteins. The SH3 domain of PSTPIP1 binds to: - **CD2:** The T-cell adhesion molecule, which was the initial basis for its identification (CD2BP1). - **PTPN22 (also known as PEP or Lyp):** A protein tyrosine phosphatase that dephosphorylates PSTPIP1, providing a negative feedback loop. - **WASP (Wiskott-Aldrich Syndrome Protein):** A key regulator of actin polymerization, linking PSTPIP1 to cytoskeletal remodeling. - **PSTPIP1 itself:** Mediating intramolecular or intermolecular interactions that regulate protein conformation [11, 18]. ### 2.2 Structural Biology and 3D Conformation High-resolution structural studies, primarily using X-ray crystallography and cryo-electron microscopy, have revealed that PSTPIP1 forms an elongated, antiparallel homodimer. The F-BAR domains of two monomers interact extensively along their concave surfaces to form a rigid, crescent-shaped structure that can bind and deform lipid membranes. This membrane deformation activity is essential for its role in podosome formation and cell migration [9]. The conformational state of PSTPIP1 is regulated by phosphorylation. In its resting state, the SH3 domain may be sequestered through an intramolecular interaction with the F-BAR domain, keeping the protein in an autoinhibited conformation. Upon phosphorylation at Y344 by c-Abl, this autoinhibition is relieved, allowing the SH3 domain to engage its effectors. The phosphatase PTPN22 binds to the SH3 domain and dephosphorylates Y344, thereby resetting the protein to its inactive state. Pathogenic mutations in the F-BAR domain disrupt this regulatory cycle, leading to a state of persistent hyperphosphorylation and constitutive activation of downstream inflammatory pathways [8, 10]. > **[Interactive 3D Protein Visualizer: Load PSTPIP1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O43586)** > > Explore the three-dimensional structure of the PSTPIP1 protein. The visualizer allows you to rotate the molecule, highlight specific domains (F-BAR, SH3), and visualize the location of clinically significant mutations such as A230T and E250K. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Pyrin Inflammasome and IL-1β Processing The most well-characterized function of PSTPIP1 is its role as a critical regulator of the **pyrin inflammasome**. Pyrin, encoded by the *MEFV* gene (mutated in Familial Mediterranean Fever), is a pattern recognition receptor that assembles an inflammasome complex in response to bacterial toxins and Rho GTPase inactivation. PSTPIP1 binds directly to pyrin via its F-BAR domain, acting as a scaffold that links pyrin to the actin cytoskeleton [10, 19, 20]. In resting cells, PSTPIP1 is phosphorylated and sequesters pyrin in an inactive complex at the cytoskeleton. Upon activation, PSTPIP1 is dephosphorylated by PTPN22, releasing pyrin to interact with the adaptor protein ASC (Apoptosis-associated Speck-like protein containing a CARD). This triggers the oligomerization of ASC into specks, recruitment of pro-caspase-1, and its autocatalytic cleavage into active caspase-1. Active caspase-1 then cleaves pro-IL-1β and pro-IL-18 into their mature, secreted forms, initiating a potent inflammatory cascade [1, 2]. Pathogenic PSTPIP1 mutations (e.g., A230T, E250K) disrupt the interaction with PTPN22, leading to a state of **hyperphosphorylation**. This hyperphosphorylated PSTPIP1 has a higher affinity for pyrin, stabilizing the complex and promoting the aberrant, constitutive activation of the pyrin inflammasome. This results in the uncontrolled release of IL-1β, driving the systemic and local inflammation characteristic of PAPA and PAMI syndromes [2, 8, 17]. ### 3.2 Regulation of S100A8/S100A9 (Calprotectin) Secretion A hallmark of PAMI syndrome is the extreme elevation of serum calprotectin (S100A8/S100A9), a heterodimeric complex that acts as a damage-associated molecular pattern (DAMP). Research by Fassl et al. and Holzinger et al. demonstrated that PSTPIP1, in complex with pyrin, is directly involved in the active secretion of S100A8/S100A9 from neutrophils and monocytes [1, 3, 8]. This secretion is an active, tubulin-dependent process that is distinct from the classical endoplasmic reticulum-Golgi pathway. Mutations in PSTPIP1, particularly those associated with PAMI syndrome (e.g., E250K, D246N), cause a dramatic upregulation of this secretory pathway, leading to the massive accumulation of calprotectin in the serum. The secreted S100A8/S100A9 then acts in an autocrine and paracrine manner to amplify the inflammatory response by binding to TLR4 and RAGE on immune cells [4, 8]. ### 3.3 Actin Cytoskeleton Dynamics, Podosome Formation, and Cell Migration As a PCH family member, PSTPIP1 is a central regulator of actin dynamics in hematopoietic cells. Through its SH3 domain, it interacts with WASP, a key nucleator of actin polymerization. This interaction is crucial for the formation of **podosomes**, which are specialized actin-rich structures that mediate cell adhesion, matrix degradation, and invasion [5, 9]. Cortesio et al. (2010) demonstrated that macrophages isolated from patients with PAPA syndrome (carrying the A230T mutation) exhibit a profound defect in podosome formation and invasive migration. This defect is due to the dysregulated interaction between mutant PSTPIP1 and WASP, leading to aberrant actin polymerization and reduced matrix degradation. This cellular phenotype may contribute to the impaired wound healing and sterile abscess formation seen in PAPA patients [9]. Furthermore, PSTPIP1 colocalizes with pyrin at the leading edge of migrating cells, suggesting a coordinated role for these two proteins in cell motility and directional migration [19, 20]. ### 3.4 Protein-Protein Interaction Network PSTPIP1 sits at the center of a complex protein-protein interaction network. Key interactors, as curated in BioGRID and STRING, include: - **PTPN22 (PEP/Lyp):** Negative regulator; dephosphorylates PSTPIP1. - **Pyrin (MEFV):** Inflammasome scaffold; central to IL-1β processing. - **CD2:** T-cell adhesion molecule. - **WASP:** Actin polymerization regulator. - **c-Abl:** Tyrosine kinase; phosphorylates PSTPIP1 at Y344. - **Siva1:** A pro-apoptotic protein, the interaction of which is modulated by anti-inflammatory drugs [6]. - **ASC:** Inflammasome adaptor protein (indirect interaction via pyrin). ```mermaid sequenceDiagram participant M as "Membrane (PIP2)" participant P as "PSTPIP1 (Dimer)" participant Abl as "c-Abl Kinase" participant Pyr as "Pyrin (MEFV)" participant Ptp as "PTPN22 (PEP)" participant ASC as "ASC Protein" participant Cas as "Pro-Caspase-1" participant IL as "Pro-IL-1β" Note over P: F-BAR domain binds to membrane P->>Abl: Y344 Phosphorylation Abl-->>P: Hyperphosphorylated State P->>Pyr: High-affinity binding (Pathogenic Mutants) Note over P,Pyr: Stabilized Complex Pyr->>ASC: Recruitment & Oligomerization ASC->>Cas: Activation & Cleavage Cas->>IL: Cleavage to Active IL-1β Note over IL: Secretion & Inflammation Ptp->>P: Dephosphorylation (Negative Feedback) Ptp-->>P: Inactive State ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Major Pathogenic Variants The clinical spectrum of PSTPIP1-associated diseases is broad, and specific mutations often correlate with distinct phenotypes. The most common and well-studied pathogenic variants are missense mutations located within the F-BAR domain. | **Mutation** | **Protein Change** | **Associated Phenotype** | **Mechanism** | **Key References** | | :--- | :--- | :--- | :--- | :--- | | **c.689C>T** | **p.A230V** | PAPA Syndrome | Hyperphosphorylation; increased pyrin binding. | [10, 11] | | **c.688G>A** | **p.A230T** | PAPA Syndrome | Hyperphosphorylation; increased pyrin binding; defective podosome formation. | [9, 11, 17] | | **c.748G>A** | **p.E250K** | PAMI Syndrome, PAPA with renal involvement | Charge switch at dimer interface; dramatic increase in S100A8/9 secretion. | [7, 8, 9] | | **c.736G>A** | **p.D246N** | PAMI Syndrome | Charge switch; similar to E250K. | [8] | | **c.773C>T** | **p.T258M** | PAPA Syndrome | Hyperphosphorylation. | [10, 11] | | **c.IV. Various** | **Splice-site variants** | Pyoderma Gangrenosum | Dominant-negative effect; protein mislocalization. | [15] | ### 4.2 Genotype-Phenotype Correlations The concept of a **"single amino acid charge switch"** was elegantly demonstrated by Holzinger et al. (2015) [8]. They showed that mutations causing a change in the local electrostatic charge at the dimer interface of the F-BAR domain (such as E250K, which changes a negatively charged glutamic acid to a positively charged lysine) are specifically associated with PAMI syndrome. These charge-switch mutations lead to a more profound dysregulation of S100A8/S100A9 secretion compared to mutations like A230T, which primarily affect phosphorylation status and are more classically associated with PAPA syndrome. This molecular distinction underpins the different clinical presentations: PAMI syndrome is characterized by hematological abnormalities (cytopenias), hepatosplenomegaly, and failure to thrive, while PAPA syndrome is dominated by pyogenic arthritis and cutaneous ulcers [2, 4, 8]. ### 4.3 Clinical Differentials and Expanding Phenotype The clinical presentation of PSTPIP1 mutations is highly variable, and the phenotype has expanded significantly beyond the classic PAPA triad. The differential diagnosis includes: - **PAPA Syndrome:** Recurrent sterile pyogenic arthritis, pyoderma gangrenosum, and cystic acne [1, 10, 12, 13, 14, 15, 16, 17, 18]. - **PAMI Syndrome:** Early-onset, with pancytopenia, hepatosplenomegaly, failure to thrive, and extremely high serum calprotectin and zinc levels [1, 2, 3, 4, 19, 20]. - **PASH Syndrome:** Pyoderma gangrenosum, acne, and suppurative hidradenitis, often without arthritis [5, 6, 7, 8, 9, 10, 11]. - **PAPASH Syndrome:** PAPA plus hidradenitis suppurativa [3, 12, 13]. - **PAID (PSTPIP1-Associated Inflammatory Diseases):** A broader umbrella term encompassing all the above, including cases with renal involvement (e.g., focal segmental glomerulosclerosis) and inflammatory bowel disease [5, 14, 15, 16, 17, 18, 19]. - **Other Associations:** Cases of systemic juvenile idiopathic arthritis (sJIA) [20], acute lymphoblastic leukemia (ALL) [1], hemophagocytic lymphohistiocytosis (HLH) [1, 2], and hidradenitis suppurativa [3, 4, 18] have been reported in patients with PSTPIP1 variants, suggesting a broader role in immune dysregulation and malignancy. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Infections and the Pyrin Inflammasome The pyrin inflammasome, regulated by PSTPIP1, is a critical component of the host defense against bacterial pathogens that inactivate Rho GTPases, such as *Clostridium difficile* (TcdB toxin) and *Burkholderia cenocepacia*. PSTPIP1's role in this pathway is therefore directly relevant to the host response to these infections. By modulating the threshold for pyrin inflammasome activation, PSTPIP1 variants could theoretically influence the severity of bacterial infections. However, direct evidence of altered susceptibility to specific pathogens in PSTPIP1-mutant patients is limited, likely due to the rarity of the disease [2]. ### 5.2 Viral Infections: SARS-CoV-2 Emerging research has linked PSTPIP1 to the host response to viral infections, particularly SARS-CoV-2. Ji et al. (2024) investigated the role of PSTPIP1 in asymptomatic SARS-CoV-2 infections. They found that stimulation of PSTPIP1 triggers proinflammatory responses, and its expression levels correlate with the magnitude of the inflammatory response to the virus. This suggests that PSTPIP1 may be a host factor that contributes to the hyperinflammatory state seen in some COVID-19 patients, and that modulating PSTPIP1 activity could be a therapeutic strategy to temper the cytokine storm [5]. ### 5.3 Bacterial Effectors and Proteomic Modulation While no direct viral oncoprotein has been shown to bind PSTPIP1, bacterial pathogens can modulate its expression or function. A quantitative proteomics study by Pei et al. (2020) on *Streptococcus suis* serotype 2 (SS2) found that the bacterial lipoprotein MetQ modulates the macrophage proteome, including proteins involved in the PSTPIP1-associated signaling network. This suggests that bacterial effectors can indirectly influence PSTPIP1 function to evade immune clearance, although the precise molecular mechanism remains to be fully elucidated [6]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Targeted Biologic Therapies Given the central role of IL-1β in the pathogenesis of PSTPIP1-associated diseases, therapeutic strategies have focused on blocking this cytokine. Several biologic agents have been used with varying degrees of success: - **Anakinra (Kineret):** A recombinant IL-1 receptor antagonist. It is the most commonly used biologic for PAPA and PAMI syndromes. While many patients show dramatic responses, particularly for arthritis and systemic inflammation, its efficacy for cutaneous manifestations like pyoderma gangrenosum is inconsistent. Some patients, especially those with specific promoter microsatellite variations, may fail to respond to anakinra [4, 13, 14]. - **Canakinumab (Ilaris):** A monoclonal antibody targeting IL-1β. It has been shown to be effective in some cases of PAPA-like syndrome, including a patient with a homozygous PSTPIP1 mutation [7]. - **TNF-α Inhibitors (e.g., Adalimumab, Infliximab):** Anti-TNF agents have been used successfully, particularly for pyoderma gangrenosum and arthritis. Dual therapy with adalimumab and tacrolimus has been reported as an effective strategy for refractory disease [16]. - **IL-18 Binding Protein (Tadekinig alfa):** Given the elevated IL-18 levels in some PAPA patients, targeting IL-18 represents a novel therapeutic avenue [8]. ### 6.2 Small-Molecule Inhibitors and Other Agents - **Colchicine:** While a mainstay for Familial Mediterranean Fever, colchicine has been reported to induce macrophage activation syndrome (MAS) in a patient with PAMI syndrome, highlighting the need for caution with this drug in PSTPIP1-mutant patients [1]. - **Methotrexate:** Has shown efficacy in controlling arthritis in some familial cases of PAPA syndrome [9]. - **Corticosteroids:** Provide rapid but often transient control of inflammation and are used as a bridge to more targeted therapies [10]. - **JAK Inhibitors:** The discovery of an IFN-γ-dependent feedback loop in PAPA syndrome pathogenesis by Lee et al. (2024) suggests that JAK inhibitors, which block IFN-γ signaling, could be a promising targeted therapy [2]. - **Investigational Approaches:** Gene therapy or RNA-based therapeutics to correct the underlying genetic defect remain theoretical but are the ultimate goal for these monogenic disorders. ### 6.3 Pharmacogenomic Considerations The response to IL-1 blockade is not uniform. Pharmacogenomic factors, such as the specific PSTPIP1 mutation and variations in the promoter region (e.g., the CCTG microsatellite), may influence drug efficacy. For instance, the failure of anakinra in an IBD patient was linked to a specific microsatellite variation in the PSTPIP1 promoter, suggesting that genetic background can modulate therapeutic outcomes [13, 14]. This underscores the need for personalized treatment approaches based on comprehensive genotyping. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Identifier / Accession** | **Description** | | :--- | :--- | :--- | | **NCBI Gene** | 9051 | Gene-specific information, genomic context, and links to related records. | | **Ensembl** | ENSG00000140368 | Genome assembly, transcripts, and comparative genomics. | | **UniProtKB** | O43586 | Protein sequence, function, domain architecture, and post-translational modifications. | | **RCSB PDB** | 2D4X, 2D4Y, 2D4Z, 3HNE | Experimentally determined 3D structures of the F-BAR and SH3 domains. | | **OMIM** | 606347 | Mendelian inheritance, phenotype descriptions, and allelic variants. | | **ClinVar** | Various (e.g., VCV000012722 for A230T) | Clinical significance of specific genetic variants. | | **Infevers** | PSTPIP1 | Registry of autoinflammatory mutations. [11] | | **STRING** | 9051 (Homo sapiens) | Protein-protein interaction networks. | | **BioGRID** | 112486 | Curated protein and genetic interactions. | | **Gene Ontology (GO)** | GO:0003779 (actin binding), GO:0005737 (cytoplasm), GO:0045087 (innate immune response) | Functional annotations for cellular component, molecular function, and biological process. | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References [1] Macharadze, D. S., & Rumyantseva, V. A. (2022). Неполная форма PAPA-синдрома, генетически детерминированный вариант в гене PSTPIP1. *Consilium Medicum*. URL: https://www.semanticscholar.org/paper/390eeafb5acdbc272f3b692b21a4dc9b2efd94f1 [2] Huang, X., Xu, M., Dai, S., Wang, M., Zheng, H., Zeng, K., & Li, L. (2021). Rare cases of PAMI syndrome in both father and son with the same missense mutation in PSTPIP1 gene and literature review. *Journal of Dermatology*. URL: https://www.semanticscholar.org/paper/cbd757fcdef165689c95d8acd801f4454ca571bf [3] Hieta, N., Nuutinen, H., Roivas, J., Salminen, K., Kujari, H., Talve, L., Toivonen, M., & Haanpää, M. (2021). Severe ulcerative proctitis, pyoderma gangrenosum, hidradenitis suppurativa and fever in a patient with a rare variant of the PSTPIP1 gene. *Clinical and Experimental Dermatology*. URL: https://www.semanticscholar.org/paper/856824da0613aa145daad4aa404ac958ecb8b7ea [4] Zhao, R., Novice, T., & Konda, S. (2022). Renal involvement as a potential feature of pyogenic arthritis, pyoderma gangrenosum, and acne syndrome with E250K mutation of PSTPIP1 gene. *JAAD Case Reports*. URL: https://www.semanticscholar.org/paper/aab590877976142dda2ea4da33116a3454eea966 [5] Zhao, R., Novice, T., & Konda, S. (2022). Renal Involvement as a Potential Feature of PAPA Syndrome with E250K Mutation of PSTPIP1 Gene. *JAAD Case Reports*. URL: https://www.semanticscholar.org/paper/2f6026cb9b811c11817fefebb4a809c7c9633b48 [6] Gowin, E., Bąbol-Pokora, K., & Januszkiewicz-Lewandowska, D. (2021). Mutation in the proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1) gene in a patient with acute lymphoblastic leukemia. *Central European Journal of Immunology*. URL: https://www.semanticscholar.org/paper/82dbd30eeb122c9b45cae5b8535a3a7217781090 [7] Calderón-Castrat, X., Bancalari-Díaz, D., Román-Curto, C., Romo-Melgar, A., Amorós-Cerdán, D., Alcaraz-Mas, L., Fernández-López, E., & Cañueto, J. (2016). PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. *British Journal of Dermatology*. URL: https://www.semanticscholar.org/paper/8e0b7bb43a6f69de1b144812c9c62b464bf7c8c6 [8] Saito, N., Minami-Hori, M., Nagahata, H., Nozaki, H., Iinuma, S., Igawa, S., Kanno, K., Kishibe, M., Kanazawa, N., & Ishida-Yamamoto, A. (2018). Novel PSTPIP1 gene mutation in pyoderma gangrenosum, acne and suppurative hidradenitis syndrome. *Journal of Dermatology*. URL: https://www.semanticscholar.org/paper/46d540f5b2fc3d090f05c2a6d0676350bfc76a4f [9] Gao, Y., & Chen, Y. (2021). Systemic juvenile idiopathic arthritis complicated with PSTPIP1 gene variant: A case report. *Global Journal of Medical and Clinical Case Reports*. URL: https://www.semanticscholar.org/paper/a2dbef0bbe09a2b93cf5c47343a9c30851eb9efe [10] Xiaobin, L., Zhiping, Z., JinHua, Y., Xia, L., & Ling, Y. (2021). PSTPIP1 Gene Mutation in a Patient with PAMI Syndrome. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/51301ad23de37b3ad43224550b55d5a57fb377ef [11] Zeeli, T., Padalon-Brauch, G., Ellenbogen, E., Gat, A., Sarig, O., & Sprecher, E. (2015). Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. *Clinical and Experimental Dermatology*. URL: https://www.semanticscholar.org/paper/e28da2e4ce81d0bdfd4968354112d643fad5aad4 [12] Lindwall, E., Singla, S., Davis, W., & Quinet, R. (2015). Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome. *Seminars in Arthritis & Rheumatism*. URL: https://www.semanticscholar.org/paper/e5f28cdecb340e360c2cbdc17f4e74ac15340165 [13] Bucchia, M., Barbarot, S., Aubert, H., Isidor, B., & Poignant, S. (2016). Syndrome PAPA-like pédiatrique et mutation du gène PSTPIP1. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/17c2101d460731c072e0820b1c855982405d418e [14] Marzano, A., Trevisan, V., Gattorno, M., Ceccherini, I., De Simone, C., & Crosti, C. (2013). Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. *JAMA Dermatology*. URL: https://www.semanticscholar.org/paper/ea3929b802857144522e5256c148fd8db552245b [15] Nesterovitch, A., Hoffman, M., Simon, M., Petukhov, P., Tharp, M., & Glant, T. (2011). Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. *Clinical and Experimental Dermatology*. URL: https://www.semanticscholar.org/paper/3f150e07ca416949735b490c273f53449f18a1ed [16] André, M., Aumaître, O., Grateau, G., Chamaillard, M., Costedoat-Chalumeau, N., Cardoso, M., Henry-Berger, J., Ramakrishna, B., Delpech, M., Piette, J., & Creveaux, I. (2010). Longest Form of CCTG Microsatellite Repeat in the Promoter of the CD2BP1/PSTPIP1 Gene Is Associated with Aseptic Abscesses and with Crohn Disease in French Patients. *Digestive Diseases and Sciences*. URL: https://www.semanticscholar.org/paper/ddab798f92a9b74eb6b143f3086b2ccab2f8096d [17] Lin, Z., Hegarty, J., Lin, T., Ostrov, B., Wang, Y., Yu, W., Kelly, A., Poritz, L., & Koltun, W. (2011). Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. *Inflammatory Bowel Diseases*. URL: https://www.semanticscholar.org/paper/644862c40eecb4041593f8806b5012f84868b71f [18] Takabe, K., Adachi, Y., Saito, H., Yamashita, T., Wakai, Y., Saito, K., & Shinohara, Y. (2013). P02-018 - PSTPIP1 gene mutations in periodic fever patients. *Pediatric Rheumatology Online Journal*. URL: https://www.semanticscholar.org/paper/9e4f8619206885d719530252e151396dd0a04be6 [19] Holzinger, D., Austermann, J., Lohse, P., Aksentijevich, I., Holland, S., Gattorno, M., Rodríguez-Gallego, C., Fessatou, S., Isidor, B., Tokio, S., Bernstein, J., Sampson, B., Sunderkoetter, C., & Roth, J. (2011). A novel mutatioin in the PSTPIP1 gene is associated with an autoinflammatory disease distinct from classical PAPA syndrome. *Pediatric Rheumatology Online Journal*. URL: https://www.semanticscholar.org/paper/e2e392b7691b8208689131b384e7c02c411e9e1b [20] Lin, Z., Hegarty, J., Lin, T., Lin, Y., Ostrov, B., Kelly, A., Poritz, L., & Koltun, W. (2011). Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient with microsatellite variation in the promoter region of